Hypermethylated promoter region of DR3 the death receptor 3 gene in rheumatoid arthritis synovial cells.код для вставкиСкачать
ARTHRITIS & RHEUMATISM Vol. 54, No. 3, March 2006, pp 779–787 DOI 10.1002/art.21637 © 2006, American College of Rheumatology Hypermethylated Promoter Region of DR3, the Death Receptor 3 Gene, in Rheumatoid Arthritis Synovial Cells Nozomi Takami,1 Kayo Osawa,1 Yasushi Miura,2 Koichiro Komai,1 Mariko Taniguchi,1 Masahiko Shiraishi,3 Keizo Sato,4 Tetsuhiro Iguchi,4 Kazuko Shiozawa,5 Akira Hashiramoto,2 and Shunichi Shiozawa6 Objective. To examine the promoter activity and protein expression of the death receptor 3 gene DR3, a member of the apoptosis-inducing Fas gene family, with particular reference to the methylation status of its promoter region in rheumatoid arthritis (RA). Methods. Genomic DNA was prepared from peripheral blood mononuclear cells obtained from healthy individuals and from patients with RA and synovial cells obtained from patients with RA and osteoarthritis. The methylation status of the DR3 promoter was analyzed by bisulfite genomic sequencing and methylation-specific polymerase chain reaction techniques. Gene promoter activity and protein expression were examined using the luciferase reporter and Western blotting techniques. Results. The promoter region of the DR3 gene contained many CpG motifs, including one CpG island that was specifically hypermethylated in synovial cells from patients with RA. Promoter assays showed that the promoter CpG island was essential for the transactivation of the DR3 gene and that forced hypermethylation of the CpG island with the bacterial methylase Sss I in vitro resulted in inhibition of the DR3 gene expression. Furthermore, the expression of DR-3 protein was downmodulated in association with methylation of the promoter CpG island in RA synovial cells. Conclusion. The CpG island in the DR3 gene promoter was specifically methylated to down-modulate the expression of DR-3 protein in rheumatoid synovial cells, which may provide resistance to apoptosis in RA synovial cells. Dr. Osawa’s work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (14657117). Dr. Shunichi Shiozawa’s work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (13204059) and by a grant from the 21st Century Center of Excellence Program (Center of Excellence for Signal Transduction Disease: Diabetes Mellitus as Model). 1 Nozomi Takami, MSc, Kayo Osawa, PhD, Koichiro Komai, PhD, Mariko Taniguchi, BSc: Kobe University FHS School of Medicine, and Kobe University Graduate School of Medicine, Kobe, Japan; 2 Yasushi Miura, MD, PhD, Akira Hashiramoto, MD, PhD: Kobe University FHS School of Medicine, Kobe University Graduate School of Medicine, and Kobe University Hospital, Kobe, Japan; 3Masahiko Shiraishi, PhD: National Cancer Center Research Institute, Tokyo, Japan; 4Keizo Sato, MD, Tetsuhiro Iguchi, MD, PhD: Kobe Rosai Hospital, Kobe, Japan; 5Kazuko Shiozawa, MD, PhD: KonanKakogawa Hospital, Kakogawa, Japan; 6Shunichi Shiozawa, MD, PhD: Kobe University FHS School of Medicine, Kobe University Graduate School of Medicine, Kobe University Hospital, and the 21st Center of Excellence, (CDE) Japan, Kobe, Japan. Address correspondence and reprint requests to Shunichi Shiozawa, MD, PhD, Department of Rheumatology, Kobe University FHS School of Medicine, 7-10-2 Tomogaoka, Sumaku, Kobe 654-0142, Japan. E-mail: firstname.lastname@example.org. Submitted for publication May 11, 2005; accepted in revised form November 10, 2005. Rheumatoid arthritis (RA) is a chronic polyarthritis of unknown cause (1,2). Studies have shown that the apoptosis-inducing death receptor Fas plays an important role in peripheral deletion of potentially autoreactive T cells and B cells (3–5) and that mice harboring mutations in Fas or Fas ligand develop characteristic systemic autoimmune diseases, including polyarthritis (6–8). However, with the exception of human autoimmune lymphoproliferative syndrome (9), a disease characterized by massive lymphadenopathy and autoimmune phenomena, mutations in Fas or Fas ligand (10) are not commonly recognized as a cause of human systemic autoimmunity. Nonetheless, defects in apoptosis may be critical to the pathogenesis of systemic autoimmunity, as exemplified by a recent 779 780 TAKAMI ET AL finding that anti–death receptor 5 (anti–DR-5), but not Fas or anti–DR-4 antibody, significantly ameliorated synovial overgrowth and experimental arthritis in mice (11). We have studied the contribution of DR-3 to the pathogenesis of RA, with reference to transactivation of the DR3 gene. DR-3 is a member of the apoptosis-inducing tumor necrosis factor (TNF) receptor superfamily that includes Fas (12–16), and its promoter region near the translation start site contains GATA, Oct-1, and two Sp1 binding sites, but without containing either the TATA or the CAAT box. Sp1 is a ubiquitously expressed zinc-finger transcription factor that supports messenger RNA (mRNA) expression in a variety of eukaryotic genes that lack a functional TATA box (17,18), and this may be important for synovial cell activation. Since plenty of CpG motifs exist in the promoter region of DR3 and since apoptotic signaling pathways are often the targets for epigenetic gene silencing (19), the present study was designed to clarify the contribution of the methylation status of the DR3 promoter to the transcriptional regulation of gene expression in patients with RA as compared with healthy individuals and patients with osteoarthritis (OA). We studied the methylation status of the CpG island in relation to promoter activity and DR-3 protein expression. Our findings indicate that DR3 promoter CpG motifs are hypermethylated in rheumatoid synovial cells; this is discussed in relation to transactivation of the DR3 gene and the pathogenesis of RA. MATERIALS AND METHODS Patients and controls. Synovial tissue from 7 RA patients and 7 OA patients who fulfilled the American College of Rheumatology (formerly, the American Rheumatism Association) criteria (20,21) were studied. Synovial tissue was obtained during joint replacement surgery in accordance with the guidelines of the Kobe University Hospital Institutional Review Board. Of the RA patients, 1 was a man, and 6 were women. Their mean ⫾ SD age was 63.3 ⫾ 13.7 years (range 34–77 years), and their mean ⫾ SD disease duration was 14.1 ⫾ 8.3 years (range 6–30 years). Of the OA patients, 3 were men, and 4 were women. Their mean ⫾ SD age was 77.4 ⫾ 6.0 years (range 71–87 years), and their mean ⫾ SD disease duration was 2.5 ⫾ 1.3 years (range 1–5 years). Diseasemodifying antirheumatic drugs prescribed for the 7 RA patients were gold sodium thiomalate (25 mg/month; n ⫽ 1), auranofin (6 mg/day; n ⫽ 1), methotrexate (16 mg/week; n ⫽ 5), and prednisolone (5 mg/day; n ⫽ 4). Blood samples were obtained from 9 RA patients and 9 healthy control subjects. Four of the control subjects were men, and 5 were women. Their mean ⫾ SD age was 25.8 ⫾ 6.4 years (range 22–37 years). Preparation of synovial cells and peripheral blood mononuclear cells (PBMCs) and extraction of DNA. Synovial tissues were minced and stirred with 1 mg/ml of collagenase (Nissui, Tokyo, Japan) in serum-free Dulbecco’s modified Eagle’s medium (DMEM; Nissui) for 1 hour, filtered through nylon mesh, and washed extensively. Cells were maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT), as described previously (22). First- or second-passage RA synovial cells and first-passage OA synovial cells were used in the studies. Peripheral blood mononuclear cells (PBMCs) were derived from blood samples obtained from RA patients and healthy control subjects. PBMCs were isolated by FicollHypaque centrifugation. DNA was extracted from the PBMCs and the synovial cells using the Wizard SV Genomic DNA Purification System (Promega, Madison, WI) according to the manufacturer’s instructions. Methylation-specific polymerase chain reaction (PCR). After denaturation in 0.3N NaOH at 37°C for 30 minutes, DNA (1 g) was treated with 1.6N sodium bisulfite and 0.5 mM hydroquinone, pH 5, at 55°C for 18 hours (23,24). For desulfonation, purified DNA was treated with 0.2N NaOH at 37°C for 10 minutes, followed by a conventional ethanolprecipitation procedure. The DR3 promoter region was amplified by PCR from sodium bisulfite–treated DNA with the use of methylation-specific primer sets (23). Amplified products were subjected to electrophoresis in nondenaturing 8% polyacrylamide gels, stained with ethidium bromide, and visualized under ultraviolet illumination. Methylated or unmethylated DNA showed 1 positive band. Partially methylated DNA showed 2 positive bands (1 for the methylationspecific primer set and 1 for the unmethylation-specific primer set). The primer pairs for amplifying methylated DNA for the region ⫺139 to ⫹53 were 5⬘-GTTTTATTTGGTTTGTTCGTTGTC-3⬘ (forward) and 5⬘-CGTACTCTCTACCCGTCGTAA-3⬘ (reverse). The primer pairs for amplifying unmethylated DNA for the region ⫺137 to ⫹53 were 5⬘-TTTATTTGGTTTGTTTGTTGTTGTT-3⬘ (forward) and 5⬘-ACTCCATACTCTCTACCCATCATAA-3⬘ (reverse). These primers, which encompass the CpG island of the DR3 promoter, were searched with MethPrimer software (available at http://www.urogene.org/methprimer/ index1.html) (25). Bisulfite genomic sequencing. Sodium bisulfite– treated DNA was extracted as described above and used as a template for amplifying the DR3 gene promoter. PCR amplification was conducted in a 20-l reaction volume containing 0.2 g of DNA, 1⫻ PCR buffer, 200 M of each dNTP, 200 nM of each primer, 1.5 mM MgCl2, and 1 unit of AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA) (24). The mixture was reacted at 95°C for 10 minutes and then amplified for 40 cycles of 95°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute, followed by reaction at 72°C for 5 minutes. This procedure results in HYPERMETHYLATED DR3 PROMOTER IN RA SYNOVIAL CELLS Figure 1. Methylation status of the DR3 gene promoter, as determined by methylation-specific polymerase chain reaction (PCR). Genomic DNA was extracted from peripheral blood mononuclear cells (PBMCs) obtained from healthy controls and patients with rheumatoid arthritis (RA) as well as from synovial cells obtained from patients with RA and osteoarthritis (OA), treated with bisulfite, and then amplified by PCR using unmethylation-specific (U) and methylationspecific (M) primers encompassing the region –137/–139 to ⫹53. PCR products were visualized in 8% polyacrylamide gels under nondenaturing conditions. Shown are the results from 3 representative subjects per group. the conversion of unmethylated cytosine to thymine, whereas methylated cytosine is unaffected. Accordingly, the ratios of methylated CpG and unmethylated CpG was defined as the ratio of the count of C to C and the ratio of the count of C to T, respectively, at each CpG site within region ⫺196 to ⫹88 (26). The primer pairs for the region ⫺467 to ⫺72 were 5⬘-TGGAATTGTAGGTGTGGTATTATTA-3⬘ (forward; CL1) and 5⬘-ACCAAATACCCCCTCTACTC-3⬘ (reverse; CR1). The primer pairs for the region ⫺191 to ⫹178 were 5⬘-ACAACTCTATCCTATACCCCTAA-3⬘ (forward; CL2) and 5⬘-TTTTTGGGATAGGGTTTAAAGT-3⬘ (reverse; CR2). PCR products were cloned into pT7Blue vector (Novagen, Madison, WI). Products were sequenced 781 using the BigDye Terminator Cycle Sequencing kit (Applied Biosystems) and an ABI 377 sequencer (Applied Biosystems). Luciferase reporter gene construct. Genomic DNA obtained from PBMCs derived from healthy subjects was amplified by PCR to generate a series of luciferase reporters. The primer pairs used for amplifying the 5⬘-flanking region of the DR3 promoter were as follows: for ⫺441/⫹139pDR3 (⫺441 to ⫹139), 5⬘-CCGGGTACCAAGTAGAGACGGCATTTCACC-3⬘ (forward; pDR3-F1) and 5⬘-CCCAAGCTTAGCCTTTAACGAGATCGGAAAGG-3⬘ (reverse; pDR3R1); for ⫺239/⫹139pDR3 (⫺239 to ⫹139), 5⬘-CCGGGTACCTTGAAGTGGTTCTCAGGGTT-3⬘ (forward; pDR3F2) and 5⬘-CCCAAGCTTCTCTTGGGACAGGGCTCAAAGCT-3⬘ (reverse; pDR3-R2); for ⫺112/⫹139pDR3 (⫺112 to ⫹139), 5⬘-CCGGGTACCTAATGAGCTCAGGTCTAGGCCG-3⬘ (forward; pDR3-F3) and 5⬘-CCCAAGCTTCTCTTGGGACAGGGCTCAAAGCT-3⬘ (reverse; pDR3-R2); for ⫹1/⫹139pDR3 (⫹1 to ⫹139), 5⬘-CCGGGTACCCGGGCCCTGCGGGCGCGGGGCTGAA-3⬘ (forward; pDR3-F4) and 5⬘-CCCAAGCTTCTCTTGGGACAGGGCTCAAAGCT-3⬘ (reverse; pDR3-R2); and for ⫺441/ ⫺294pDR3 (⫺441 to ⫺294), 5⬘-CCGGGTACCAAGTAGAGACGGCATTTCACC-3⬘ (forward; pDR3-F1) and 5⬘CCCAAGCTTGAGGTTGGGCCAAAAGTACC-3⬘ (reverse; pDR3-R3). The Kpn I and Hind III recognition sequences were added to the 5⬘ ends of the forward and reverse primers, respectively. The PCR products were cloned into the Kpn I–Hind III site of the pGL3-Enhancer vector (Promega). We used TFSearch software (available at http://mbs.cbrc.jp/ research/db/TFSEARCH.html) to search for transcription factor binding sites. In vitro DNA methylation. The DR3 reporter gene constructs (–441/⫹139pDR3, –239/⫹139pDR3, and –112/ ⫹139pDR3) were methylated in vitro using bacterial methylase Sss I (New England Biolabs, Beverly, MA). Briefly, the DR3 reporter gene construct (40 g) was incubated at 37°C for 2 hours with 40 units of Sss I in 50 mM NaCl, 10 mM Tris HCl, 10 mM MgCl2, and 1 mM dithiothreitol (pH 7.9) supplemented with 160 M S-adenosylmethionine. Methylated plasmids were purified with the use of the Wizard DNA Clean-Up system (Promega). Table 1. Methylation status of the DR3 promoter, as determined by the methylation-specific polymerase chain reaction method* Methylation status PBMCs Healthy controls RA patients Synovial cells OA patients RA patients No. of subjects Unmethylated Partially methylated Methylated 9 9 9 (100) 9 (100) 0 0 0 0 7 7 2 (29) 0 5 (71) 6 (86) 0 1 (14) P† 0.21 * Values are the number (%) of subjects. PBMCs ⫽ peripheral blood mononuclear cells; RA ⫽ rheumatoid arthritis; OA ⫽ osteoarthritis. † Determined by chi-square test. 782 TAKAMI ET AL Figure 2. Methylation status of the DR3 gene promoter, as determined by bisulfite sequencing. A, Promoter construct, showing the CpG island, additional CpG motifs, the ATG translation start site, and position ⫹1, the latter 2 of which were designed. Bisulfite-treated genomic DNA derived from peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects and patients with rheumatoid arthritis (RA) and derived from synovial cells obtained from patients with RA and osteoarthritis (OA) was cloned into pT7Blue vector and then sequenced. A total of 7–10 genomic clones of the DR3 promoter were obtained from each subject (numbered vertically). Each circle represents a CpG dinucleotide; intervening bases were omitted. B, Ratios of methylated and unmethylated CpG motifs. In the CpG island encompassing –196 to ⫹88 (ATG translation start site), the ratios of C to C and of C to T were determined in each 5–10 clones derived from PBMCs from healthy subjects (n ⫽ 2) and RA patients (n ⫽ 2) and in those derived from synovial cells from RA patients (n ⫽ 7) and OA patients (n ⫽ 7). The presence of ⬎65% C to C was arbitrarily designated as methylated, the presence of ⬎65% C to T was designated as unmethylated, and the presence of C to C and of C to T at ⱖ35% but ⱕ65% was designated as partially methylated. HYPERMETHYLATED DR3 PROMOTER IN RA SYNOVIAL CELLS Table 2. 783 Methylation status of the DR3 promoter, as determined by the bisulfite sequencing method* Methylation status PBMCs Healthy controls RA patients Synovial cells OA patients RA patients No. of subjects Unmethylated Partially methylated Methylated 2 2 2 (100) 2 (100) 0 0 0 0 7 7 3 (43) 0 4 (57) 3 (43) 0 4 (57) P† 0.008 * Values are the number (%) of subjects. PBMCs ⫽ peripheral blood mononuclear cells; RA ⫽ rheumatoid arthritis; OA ⫽ osteoarthritis. † Determined by chi-square test, comparing only the unmethylated versus the methylated group. Luciferase reporter assay. COS-7 and 293T cells (1 ⫻ 105) were transfected with 200 ng of pGL3-Enhancer vector containing the DR3 reporter gene constructs (⫺441/ ⫹139pDR3, ⫺239/⫹139pDR3, ⫺112/⫹139pDR3, ⫹1/⫹139pDR3, or ⫺441/⫺294pDR3) by using Lipofectamine Plus reagent (Invitrogen, San Diego, CA) (27). As an internal control for transfection efficiency, 5 ng of pRL-TK (Promega) containing the herpes simplex virus thymidine kinase promoter in the upstream of Renilla luciferase was cotransfected. Cell lysate (20 l) was analyzed for luciferase activity using the Dual-Luciferase Reporter Assay (Promega) in a Luminoskan (Labsystems, Tokyo, Japan). Activities of both firefly and Renilla luciferases were measured, and the activity of firefly luciferase was normalized to that of Renilla luciferase. Data were expressed as the mean ⫾ SD of 2 independent experiments. Western blotting. Cells (1 ⫻ 106) were suspended in 100 l of hypotonic lysis buffer (25 mM Tris, pH 8.0, 1% Nonidet P40, 150 mM NaCl, 1.5 mM EGTA, 0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 10 mM sodium orthovanadate, and 3 mg/ml of aprotinin), maintained on ice for 10 minutes, and the protein fraction was obtained by centrifugation at 15,000 revolutions per minute for 10 minutes (28). Protein (20 g) was subjected to electrophoresis in 10–20% sodium dodecyl sulfate– polyacrylamide gel electrophoresis gels (Biocraft, Tokyo, Japan) and transferred to an Immobilon-P membrane (Millipore, Bedford, MA). The membrane was then incubated with mouse IgG anti-human DR-3 antibody (eBioscience, San Diego, CA) and then reacted with horseradish peroxidase–conjugated anti-mouse IgG antibody and ECL enhanced chemiluminescence reagent (Amersham Bioscience, Piscataway, NJ). The density of the blots was scanned and quantified using NIH Image/Image J software (National Institutes of Health, Bethesda, MD; available at http:// rsbweb.nih.gov/ij/). Statistical analysis. The chi-square test and Student’s 2-tailed independent t-test were used to determine the significance of differences between groups, as appropriate. RESULTS Methylation status of the DR3 promoter. PCR amplification of the CpG island encompassing the region –196 to ⫹139 by use of methylation-specific and unmethylation-specific primers revealed that this region was consistently unmethylated in PBMCs from healthy controls and patients with RA (Figure 1). In contrast, synovial cells from patients with OA were either unmethylated or partially methylated. Furthermore, synovial cells from patients with RA were mostly methylated. Table 1 summarizes the individual methylation status of PBMCs from RA patients and healthy controls and of synovial cells from RA and OA patients, as examined by methylation-specific and unmethylationspecific PCR. Bisulfite genomic sequencing confirmed that the CpG island (–196 to ⫹139) was consistently unmethylated in PBMCs from all healthy individuals and the patients with RA (Figure 2A). The CpG island, however, was highly methylated in synovial cells from patients with RA and to a lesser extent in synovial cells from patients with OA. When the percentage of methylation in the region –196 to ⫹88 (ATG translation start site) was plotted, we found that synovial cells from RA patients were highly methylated as compared with those from OA patients (Figure 2B). Table 2 summarizes the individual methylation status of PBMCs from RA patients and healthy controls and of synovial cells from RA and OA patients, as examined by the bisulfite sequencing method. The results showed that synovial cells from patients with RA were predominantly hypermethylated as compared with those of OA (P ⫽ 0.008), which 784 TAKAMI ET AL Figure 3. Luciferase promoter assays. A, DR3 gene map, showing the positions of the CpG island, the transcription factor binding sites, the additional CpG motifs, the ATG translation start site, and the DR3 reporter gene constructs encompassing the region –441 to ⫹139 (–441/⫹139pDR3, –239/⫹139pDR3, –112/⫹139pDR3, ⫹1/⫹139pDR3, and –441/–294pDR3), which were used in the dual-luciferase (LUC) reporter assay. B, The DR3 reporter constructs were examined for luciferase activity in COS-7 and 293T cells using a dual-luciferase reporter assay (top). The DR3 reporter constructs were then either left untreated or were treated with Sss I for 2 hours to increase DNA methylation and were assayed for luciferase activity in COS-7 and 293T cells (bottom). Values are the mean ⫾ SD. P values were determined by Student’s 2-tailed independent t-test. ND ⫽ not done. indicates that the CpG island in the DR3 gene promoter is hypermethylated in RA synovial cells in a diseasespecific manner. Furthermore, the lymphocytes infiltrating to the rheumatoid synovium were also significantly methylated, with samples from 4 of 12 patients (33%) being unmethylated, 7 of 12 (58%) being partially methylated, and 1 of 12 (8%) being methylated, as determined by the methylation-specific PCR method. Promoter activity. COS-7 and 293T cells were transfected with luciferase reporter gene constructs driven HYPERMETHYLATED DR3 PROMOTER IN RA SYNOVIAL CELLS 785 Figure 4. Methylation status and DR-3 protein expression. A, Western blotting for DR-3 protein (top) and for the methylation status of the DR3 CpG island (bottom) in peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects (n ⫽ 5) and in synovial cells obtained from patients with rheumatoid arthritis (RA) (n ⫽ 5). Findings in the PBMCs and synovial samples were consistent with each other. B, Densitometry data derived from the Western blots shown in A, as determined with the use of the National Institutes of Health (NIH) Image/Image J software. C, Western blotting for DR-3 protein (top) and for the methylation status of the DR3 CpG island (bottom) in synovial cells from patients with RA (n ⫽ 3) and patients with osteoarthritis (OA) (n ⫽ 3). D, Densitometry data derived from the Western blots shown in C, as determined with the use of the NIH Image/Image J software. Horizontal lines in B and D indicate the mean; P values were determined by Student’s 2-tailed independent t-test. by the truncated DR-3 promoters ⫺441/⫹139pDR3, ⫺239/⫹139pDR3, ⫺112/⫹139pDR3, ⫹1/⫹139pDR3, and ⫺441/⫺294pDR3 and assayed for luciferase activity (Figure 3A). Comparable levels of promoter activity were detectable for promoter regions ⫺441/⫹139pDR3, ⫺239/ ⫹139pDR3, and ⫺112/⫹139pDR3, whereas promoter regions ⫹1/⫹139pDR3 and ⫺441/⫺294pDR3 were essentially inert (Figure 3B, top). When the ⫺441/⫹139pDR3, ⫺239/⫹139pDR3, and ⫺112/⫹139pDR3 constructs of the DR3 promoter were experimentally methylated in vitro by the use of bacterial methylase Sss I, the promoter activities were essentially abolished (Figure 3B, bottom). These findings indicate that promoter activity in the CpG island upstream of exon 1 is essential for the transactivation of the DR3 gene. Methylation status and protein expression. We next studied the relationship between the methylation status of the CpG island and protein expression. Western blotting studies using PBMCs from healthy individuals and synovial cells from RA patients showed that the expression of DR-3 protein was decreased in RA synovial cells (n ⫽ 5) as compared with healthy PBMCs (n ⫽ 5) (Figure 4A). We also confirmed that the level of expression of DR-3 protein in PBMCs was comparable 786 TAKAMI ET AL in the RA patients and healthy controls (data not shown). The expression of DR-3 protein was significantly decreased in association with methylation of the CpG island (P ⫽ 0.008), as demonstrated by comparison of the PBMCs from healthy controls with the synovial cells from RA patients (Figure 4B). Furthermore, the expression of DR-3 protein was also decreased in the RA synovial cells (n ⫽ 3) as compared with OA synovial cells (n ⫽ 3) (P ⫽ 0.03) (Figures 4C and D). DISCUSSION We found that the CpG island of the DR3 gene promoter was highly methylated in RA synovial cells as compared with OA synovial cells. Previous studies have shown that plenty of CpG motifs exist in the promoter region of apoptosis-inducing TNF receptor superfamily genes (29) and that apoptotic signaling pathways are often subjected to epigenetic gene silencing (19,30). However, with the exception of the study by Petak et al (31), who showed an inverse correlation between the methylation status of the Fas gene promoter and Fas protein expression by comparing different tumor cell lines, the promoter activity of apoptosis-inducing genes was not directly studied in the same cell. Thus, the molecular relationship among the methylation status of the CpG island, the expression of the apoptosispromoting gene, and the activity of the disease remained unclear. In the present study, we found that transactivation of the DR3 gene was down-modulated by methylation of the promoter CpG island and the expression of DR-3 protein was significantly decreased in association with the decreased methylation status of the promoter CpG island. Several transcription factors, such as GATA, Oct-1, or Sp1, can bind the CpG island. In particular, Sp1 is a ubiquitously expressed zinc-finger transcription factor that supports mRNA expression in a variety of eukaryotic genes that lack the functional TATA box (17,18). Among Sp family proteins, Sp1 and Sp3 were shown to be ubiquitously expressed in human tissues, and transcriptional activity enhanced by Sp1 was shown to be suppressed by Sp3 (32). Therefore, in such genes, CpG motifs may play an essential role in gene expression, especially in the expression of the DR3 gene (33,34). This idea needs further investigation. Expression of DR-3 has been shown to be increased in lymphocytes (14), which may be dependent on the fact that the CpG island of the DR3 promoter region was almost completely unmethylated in PBMCs from patients with RA and healthy individuals, as shown in Figure 2A and Tables 1 and 2. In contrast, our results indicated that the CpG island was highly methylated in RA synovial cells and in a synovial tissue lymphocyte fraction as well, which indicates that inflammatory conditions unique to rheumatoid joints could be responsible for the heightened CpG methylation in RA. Furthermore, our finding that expression of DR-3 was downregulated in RA synovial cells as compared with the noninflammatory OA synovial cells (see Figures 4C and D) may be responsible for the defect in apoptosis induction against TNF-like molecule 1A (TL1A), a physiologic ligand of DR-3, both in vitro (35) and in vivo (36). Our finding may also be related to findings of other studies shown that apoptosis is defective in vivo in rheumatoid synovium (37,38). In summary, we found one CpG island in the DR3 promoter region that was highly methylated in RA synovial cells. The CpG island is essential for the transactivation of the DR3 gene, and the expression of DR-3 protein was decreased in association with the increased methylation of the promoter CpG island of the DR3 gene. ACKNOWLEDGMENT We thank Dr. M. Lamphier for critical reading of the manuscript. REFERENCES 1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907–16. 2. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167–79. 3. Russell JH, Rush B, Weaver C, Wang R. Mature T cells autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci U S A 1993;90:4409–13. 4. Singer GG, Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994;1:365–71. 5. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo: dual roles for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996;87:319–29. 6. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356: 314–7. 7. Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci U S A 1993;90:1756–60. 8. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969–76. 9. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair HYPERMETHYLATED DR3 PROMOTER IN RA SYNOVIAL CELLS 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935–46. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107–13. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003;171:1061–9. Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-B. Curr Biol 1996;6:1669–76. Kitson J, Raven T, Jiang YP, Goeddel DV, Giles KM, Pun KT, et al. A death-domain-containing receptor that mediates apoptosis. Nature 1996;384:372–5. Chinnaiyan AM, O’Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996;274:990–2. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169: 1747–56. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301–5. Briggs MR, Kadonaga JT, Bell SP, Tjian R. Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 1986;234:47–52. Saffer JD, Jackson SP, Annarella MB. Developmental expression of Sp1 in the mouse. Mol Cell Biol 1991;11:2189–99. Jones PA. Cancer: death and methylation. Nature 2001;409:143–4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039–49. Hashiramoto A, Sano H, Maekawa T, Kawahito Y, Kimura S, Kusaka Y, et al. c-myc antisense oligodeoxynucleotides can induce apoptosis and down-regulate Fas expression in rheumatoid synoviocytes. Arthritis Rheum 1999;42:954–62. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821–6. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 787 display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827–31. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427–31. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999;59:2029–33. Kawasaki H, Komai K, Nakamura M, Yamamoto E, Ouyang Z, Nakashima T, et al. Human wee1 kinase is directly transactivated by and increased in association with c-Fos/AP-1: rheumatoid synovial cells overexpressing these genes go into aberrant mitosis. Oncogene 2003;22:6839–44. Kawasaki H, Komai K, Ouyang Z, Murata M, Hikasa M, Ohgiri M, et al. c-Fos/activator protein-1 transactivates wee1 kinase at G1/S to inhibit premature mitosis in antigen-specific Th1 cells. EMBO J 2001;20:4618–27. Rudert F, Visser E, Forbes L, Lindridge E, Wang Y, Watson J. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. DNA Cell Biol 1995;11: 931–7. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1–7. Petak I, Danam RP, Tillman DM, Vernes R, Howell SR, Berczi L, et al. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 2003;10:211–7. Suske G. The Sp-family of transcription factors. Gene 1999;238: 291–300. Jones AP, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415–28. Hermann A, Gowher H, Jeltsch A. Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 2004;61: 2571–87. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002;16:479–92. Shimizu M, Miura Y, Hashiramoto A, Shimizu T, Murao H, Shiozawa S. TL1A, a specific ligand for death receptor 3 and agonistic anti-DR3 antibody, inhibit type II collagen-induced arthritis in mice [abstract]. Arthritis Rheum 2004;50 Suppl 9:S569. Baier A, Meineckel I, Gay S, Pap T. Apoptosis in rheumatoid arthritis. Curr Opin Rheumatol 2003;15:274–9. Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K, et al. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum 1995;38: 485–91.